Evidence map›Paper›PMID 41463249›Full record

ArticleCancers2025

Mortality and Non-Fatal Clinical Outcomes After the Most Common Cancers in People with HIV: A Multicohort Collaboration.

Alisa Timiryasova, Lauren Greenberg, Pere Domingo, Philip E Tarr, Alexander Egle, Charlotte Martin, Cristina Mussini, Ferdinand Wit, Antonella Cingolani, Clara Lehmann and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Alisa TimiryasovaCHIP-Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark.ORCID 0009-0008-7451-8116
Lauren GreenbergCHIP-Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark.
Pere DomingoHIV Infection Unit, Hospital de la Santa Creu I Sant Pau, Sant Quintí, 89, 08025 Barcelona, Spain.ORCID 0000-0003-1138-5770
Philip E TarrSwiss HIV Cohort Study (SHCS), Kantonsspital Baselland, University of Basel, 4101 Bruderholz, Switzerland.ORCID 0000-0002-1488-5407
Alexander Egle3rd Medical University Department, Paracelsus Medical University, 5020 Salzburg, Austria.ORCID 0000-0003-0648-4416
Charlotte MartinInfectious Diseases Department, CHU Saint-Pierre, Université Libre de Bruxelles, 322 rue Haute, 1000 Brussels, Belgium.ORCID 0000-0002-8995-6230
Cristina MussiniModena HIV Cohort, Università Degli Studi Di Modena and Reggio Emilia, 41125 Modena, Italy.
Ferdinand WitAIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort, Stichting HIV Monitoring & Department of Internal Medicine, Amsterdam UMC, University of Amsterdam, 1018 VN Amsterdam, The Netherlands.
Antonella CingolaniItalian Cohort Naive Antiretrovirals (ICONA), Fondazione Policlinico A. Gemelli, IRCCS, L.go A. Gemelli 8, 00168 Roma, Italy.ORCID 0000-0002-3793-2755
Clara LehmannDepartment I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.
Antonella CastagnaSan Raffaele Scientific Institute, Università Vita-Salute San Raffaele, 20132 Milano, Italy.
Kathy PetoumenosThe Australian HIV Observational Database (AHOD), Kirby Institute, University of New South Wales (UNSW), Sydney 2052, Australia.
Caroline A SabinCentre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London NW3 2PF, UK.ORCID 0000-0001-5173-2760
Fabrice BonnetCHU de Bordeaux and Bordeaux University, BPH, INSERM U1219, 33076 Bordeaux, France.
Jens LundgrenCHIP-Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark.
Martina BottanelliSan Raffaele Scientific Institute, Università Vita-Salute San Raffaele, 20132 Milano, Italy.ORCID 0000-0003-1162-3513
Sean HoseinEuropean AIDS Treatment Group, 1000 Brussels, Belgium.
Christina CarlanderDepartment of Infectious Diseases, Karolinska University Hospital, 141 86 Stockholm, Sweden.
Alain AmstutzDivision of Clinical Epidemiology, University Hospital Basel, 4051 Basel, Switzerland.ORCID 0000-0003-1716-993X
Katharina Grabmeier-PfistershammerDepartment of Dermatology, Medical University of Vienna, 1090 Vienna, Austria.
Harmony GargesViiV Healthcare, Global Medical, Durham, NC 27709, USA.
Andrea MarongiuReal World Evidence Virology Department, Gilead Sciences, London WC1V 7EE, UK.
Lital A YoungGlobal Medical Affair, Merck Sharp & Dohme, Rahway, NJ 07065, USA.
Lars PetersCHIP-Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark.
Lene RyomCHIP-Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark.
On Behalf Of The D A D And Respond Study Groups

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cancercomorbiditiesHIVimmune statusmodifiable risk factorsmortalitynon-fatal clinical outcomes

Identifiers

PMID41463249
PMCPMC12731807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.